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Extended Duration Dual Antiplatelet Therapy After
Percutaneous Coronary Intervention in Patients With
Peripheral Arterial Disease: A Meta-Analysis
Hua Linga, e, Ebony Andrewsb, David Ombengic, Fang Lid

Abstract
Background: Patients with peripheral arterial disease (PAD) undergoing percutaneous coronary intervention (PCI) are at elevated risk of
ischemic and bleeding events. However, the optimal duration of dual
antiplatelet therapy (DAPT) after PCI in patients with PAD remains
unclear.
Methods: A systematic literature search was performed through
June 2017 using PubMed, EMBASE and Cochrane databases with
the following key terms: “dual antiplatelet therapy”, “P2Y12 inhibitor”, “myocardial infarction”, “percutaneous coronary intervention”,
“stent”, “peripheral arterial disease”, and “ankle-brachial index”. The
analysis was restricted to randomized trials published in English in
patients with PAD receiving extended DAPT (> 12-month) after PCI.
Overall analysis was performed using Review Manager 5.3 with the
Mantel-Haenszel method.
Results: Two randomized controlled trials involving 895 patients
were included in this review. Compared to the placebo group, there
was no statistical significance in the occurrence of major adverse
cardiovascular and cerebrovascular events (MACCE) in patients receiving extended DAPT (odds ratio (OR) 0.76, 95% confidence interval (CI) 0.37 - 1.57; P = 0.46). The results were associated with
substantial heterogeneity (I2 = 71%, P = 0.07). Extended DAPT was
not significantly associated with increased moderate/severe bleeding
events (OR 1.63, 95% CI 0.84 - 3.18; P = 0.15; I2 = 0%, P = 0.59).
The extended DAPT was associated with 82% relative risk reduction
in the events of definite/probably stent thrombosis.
Conclusions: Among patients with PAD, extended DAPT after PCI
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resulted in a non-significant difference in ischemic and bleeding
events compared to placebo, respectively. The routine use of extended
DAPT in this cohort should be carefully evaluated.
Keywords: DAPT, PCI, PAD

Introduction
Peripheral arterial disease (PAD) is associated with more
extensive and calcified coronary atherosclerosis, constrictive arterial remodeling, and greater disease progression in
patients with coronary artery disease, thus contributing to adverse cardiovascular outcomes [1]. It is estimated that PAD
affects approximately 8.5 million people in the United States
[2]. It is reported that two out of three patients with PAD had
coexistent coronary arterial disease (CAD) and one in five
patients with CAD had coexistent PAD [3, 4]. Patients with
PAD undergoing percutaneous coronary intervention (PCI)
are at elevated risk of adverse clinical events. The data from
the Dutch Stent Thrombosis Registry found that PAD was an
independent risk factor associated with 5.62-fold increased
odds of late (> 30 days) stent thrombosis [5]. Patients with
PAD were also reported to have a 2-fold increase risk of
death and a trend toward higher major bleeding complications after PCI [4, 6]. Dual antiplatelet therapy (DAPT) with
aspirin and a P2Y12 inhibitor after PCI is generally recommended to reduce the risk of stent thrombosis and ischemic
events, which unfortunately may be offset by the increased
risk of bleeding [7]. The optimal duration of DAPT has been
debated in the past few decades and decisions regarding duration of DAPT require a comprehensive assessment of the
benefits of treatment, bleeding risk, and patient preference.
In the PEGASUS-TIMI 54 (Prevention of Cardiovascular
Events in Patients With Prior Heart Attack Using Ticagrelor
Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) trial, DAPT with a median
treatment duration of 33 months achieved approximately
40% reduction in cardiovascular death, myocardial infarction
(MI), or stroke in patients with PAD, compared to patients
without PAD [6]. A non-significant increase of Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding was observed in patients with PAD treated with DAPT
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Figure 1. Summary of the study selection and exclusion process.

in the PEGASUS-TIMI 54 trial. Similar findings have been
reported in the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management,
and Avoidance) trial with 40% reduction in MI in patients
received DAPT for 28 months [8]. That said, patients with
PAD in CHARISMA trial experienced almost 70% increase
of minor bleeding compared to aspirin monotherapy (20.4%
vs. 34.4%). Considering the elevated risk of ischemic and
bleeding events in patients with PAD undergoing PCI, it is
uncertain about whether DAPT should be extended beyond
12 months based on the benefit-risk profile. We conducted a
meta-analysis on this topic to better understand the benefits
and risks of DAPT beyond 12-month for secondary prevention in patients with PAD undergoing PCI.

Methods
The studies included in the meta-analysis to evaluate the duration of DAPT in patients with PAD undergoing PCI were identified by conducting a systematic review of literature indexed
in database PubMed, EMBASE and Cochrane databases.
138
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Key words used to conduct the search were “dual antiplatelet
therapy”, “P2Y12 inhibitor”, “myocardial infarction”, “percutaneous coronary intervention”, “stent”, “peripheral arterial
disease”, and “ankle-brachial index”. The literature search was
performed through June 2017. In addition, published conference abstracts, review articles, and editorials were reviewed
for further information.
The meta-analysis included original research that met the
following inclusion criteria: 1) randomized controlled study as
design; 2) published in English; 3) conducted in patients with
PAD undergoing coronary stenting with either drug-eluting stents (DES) or bare metal stents; and 4) compared the efficacy
of extended DAPT (> 12-month) vs. non-extended DAPT (≤
12-month). The exclusion criteria were as follows: 1) studies
whose analysis did not include patients with PAD; 2) studies
that did not have controls.
The primary endpoint for this analysis was the incidence
of MACCE, defined as a composite of all-cause death, MI, and
stroke. Incidence of GUSTO (the Global Use of Strategies to
Open Occluded Coronary Arteries) moderate/severe bleeding
was used for the safety endpoint. Events of definite or probable
stent thrombosis, MI, cardiac death, and all-cause death were
also evaluated.
This meta-analysis followed the guidelines of the PRISMA Statement 2009 [9]. The two authors independently assessed the eligibility of trials and extracted the data. Disagreements were resolved by consensus. The Cochrane Risk of Bias
Tool was used to assess bias risk. All statistical analyses were
performed by Review Manager 5.3 (Nordic Cochrane Centre,
Cochrane Collaboration) using the Mantel-Haenszel method
with either random effects or fixed effects models based on
the level of heterogeneity. Odds ratio (OR) of efficacy and
safety end points were calculated from the included studies
in patients with PAD undergoing PCI receiving extended vs.
non-extended DAPT. We tested heterogeneity of the included
studies with Cochran Q statistics and the extent of inconsistency between results with I2 statistics with significance set at a
P value of 0.10. Data are presented as OR with 95% confidence
intervals (CI), with two-tailed P values and statistical significance set at P value < 0.05.

Results
Overall, 185 citations met the search criteria to be assessed.
After deleting 59 duplications, 126 citations were reviewed
in detail for eligibility. Most citations were excluded because
they were review articles, abstracts, editorials, non-randomized
registry studies, or not relevant to our topic (Fig. 1). Particularly, the CHARISMA trial was excluded because it compared
DAPT vs. aspirin monotherapy in patients with PAD [8]. The
PEGASUS-TIMI 54 trial was excluded because it included patients with MI that occurred 1 - 3 years prior to enrollment [6].
Furthermore, patients in PEGASUS-TIMI 54 trial were also
not required to have a history of PCI with stenting.
After exclusion, two randomized controlled trials involving 895 patients were included in this analysis. The main description of both studies and the participants’ characteristics

Articles © The authors | Journal compilation © Cardiol Res and Elmer Press Inc™ | www.cardiologyres.org

Ling et al

Cardiol Res. 2018;9(3):137-143

Table 1. Summary of the DAPT Trial and PRODIGY Trial
The PRODIGY trial

The DAPT trial

No of patients

1970

11,648

No of patients with PAD

246

649

Randomization groups

Aspirin 75 - 160 mg/d + clopidogrel
75 mg/d vs. aspirin + placebo

Aspirin 75 - 162 mg/d + clopidogrel 75 mg/d
or prasugrel 10/5 mg/d vs. aspirin + placebo

Follow-up

≤ 6-month vs. 24-month

12-month vs. 30-month

Age among patients with PAD (SD)

74.5 (8.94)

66.2 (9.57)

Male among patients with PAD

76.83%

70.42%

Diabetes mellitus among patients with PAD

33.74%

44.29%

Hypertension among patients with PAD

87.40%

87.98%

Smoking among patients with PAD

15.45%

28.55%

Congestive heart failure among patients with PAD

6.50%

14.73%

Prior PCI among patients with PAD

23.98%

40.87%

Prior CABG among patients with PAD

17.89%

25.15%

Prior MI among patients with PAD

40.65%

30.77%

   STEMI among patients with PAD

20.32%

4.62%

   NSTE-ACS among patients with PAD

52.44%

26.81%

   Stable angina among patients with PAD

27.23%

44.53%

Indication for PCI

CABG: coronary artery bypass grafting; MI: myocardial infarction; PAD: peripheral artery disease; SD: standard deviation.

are listed in Table 1. The PRODIGY (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study) trial was a randomized, multicenter, openlabel study, and the subanalysis of PRODIGY trial assessed
the efficacy and safety of prolonged (24-month) vs. short (≤
6-month) DAPT (clopidogrel plus aspirin) in 246 and 1,724
patients with and without PAD undergoing PCI, respectively
[10]. The DAPT trial was a randomized, double-blind, placebo-controlled trial, and the subanalysis of the DAPT trial evaluated the efficacy of extended DAPT (clopidogrel or prasugrel
plus aspirin; 30-month vs. 12-month) in reducing ischemic
events and the safety profile of extended DAPT in 10,999
non-PAD vs. 649 PAD patients [11]. Of note, approximately
half participants in both the PRODIGY and the DAPT trial
received everolimus-eluting stent or zotarolimus-eluting stent,
which are considered as new-generation DES with less risk of
stent thrombosis.
The incidence of MACCE was 12.8% (56/437 patients)
when receiving extended DAPT vs. 15.5% (71/458 patients)
in patients received non-extended DAPT, representing a nonsignificant relative risk reduction (OR = 0.76; 95% CI 0.37 -

1.57; P = 0.46) (Fig. 2). The Chi-square test for heterogeneity
was significant at a level of less than 0.10 (P = 0.07). The I2
value was 70%. These quantitative results suggest there was
study variability.
The occurrence of GUSTO moderate/server bleeding was
5.0% (22/437 patients) when receiving extended DAPT vs.
3.1% (14/458 patients) when receiving non-extended DAPT
(OR = 1.67; 95% CI 0.84 - 3.32; P = 0.14) (Fig. 3). Extended
DAPT was not significantly associated with increased GUSTO
moderate/severe bleeding events, without heterogeneity between studies.
The extended DAPT was associated with 82% relative
risk reduction in the events of definite/probably stent thrombosis, compare to the non-extended DAPT (OR = 0.18; 95%
CI 0.05 - 0.68; P = 0.01) (Fig. 4). The risk reduction represented an absolute risk difference of 2.60% or a number needed to
treat of 38 to prevent one stent thrombosis over an extended
duration of DAPT. However, this significant reduction in stent
thrombosis was not accompanied by any significant reduction
in MI, cardiac death, or all-cause death. (Fig. 5-7) Though
there was little heterogeneity in the analysis of stent thrombo-

Figure 2. MACCE associated with a short versus extended DAPT use in patients with PAD after PCI.
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Figure 3. GUSTO moderate/severe bleeding events associated with a short versus extended DAPT use in patients with PAD
after PCI.

Figure 4. Definite or probable stent thrombosis events associated with a short versus extended DAPT use in patients with PAD
after PCI.

Figure 5. MI events associated with a short versus extended DAPT use in patients with PAD after PCI.

sis and MI, the analysis of cardiac death and all-cause death
were associated with substantial heterogeneity, indicating
study variability.
The risk of bias in included studies was low or unclear
in most areas in both studies (Fig. 8). The performance bias
and attrition bias were the main potential sources of bias in
the PRODIGY trial. The open-label design of the PRODIGY

trial may have introduced a potential for performance bias, and
more patients in the short-term arm were reported to discontinue clopidogrel after the first month (12% vs. 0.2%), which was
allowed in patients who were randomized to a BMS. However,
the discontinuation rate was not reported in the PAD population, so it is unclear about attrition bias in the subgroup analysis of the PRODIGY trial.

Figure 6. Cardiac death events associated with a short versus extended DAPT use in patients with PAD after PCI.

Figure 7. All-cause death events associated with a short versus extended DAPT use in patients with PAD after PCI.
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Figure 8. Risk of bias graph for the studies included in this systematic
review. Green +: yes (low risk of bias); yellow ?: unclear; red -: no (high
risk of bias).

Discussion
Our meta-analysis of two randomized controlled trials involving 895 patients with PAD undergoing PCI found a non-statistically significant reduction of MACCE in patients receiving extended DAPT. The extended duration of DAPT was not
significantly associated with increased GUSTO moderate/severe bleeding events either. A substantial reduction of definite/
probably stent thrombosis was observed in the extended DAPT
group. Unfortunately, the reduction of stent thrombosis alone
was not able to reduce the occurrence of MI, cardiac death, and
all-cause death significantly. The analysis of MACCE, cardiac
death, and all-cause death were associated with substantial heterogeneity.
The subanalysis of the DAPT trial and PRODIGY trial
found that PAD was associated with increased risk of ischemic and bleeding events after PCI, which were consistent with the previous findings in the CHARISMA trial and
PEGAUSIS-TIMI 54 trial. In general, the PAD patients
were usually older and more likely to have hypertension,
MI, multiple stents, and diabetes mellitus. In the DAPT trial

and PRODIGY trial, patients with PAD were associated with
higher rates of stent thrombosis, MI, MACCE compared with
patients without PAD, indicating that PAD is a risk factor of
adverse health outcomes (Table 2). The incidence of GUSTO
moderate/severe bleeding was significantly higher in patients
with PAD compared with patients without PAD in the DAPT
trial, though the rate of bleeding-related death was similar
[11]. Interestingly, the increased rate of GUSTO moderate/
severe bleeding was not observed in the PRODIGY trial,
which could be explained by the small sample size and inadequate power [10]. Due to the evaluated risk of ischemic and
bleeding events in patients with PAD, it will be necessary to
investigate if the duration of DAPT should be tailored based
on the status of PAD.
Current guidelines recommend at least 12-month treatment of DAPT in patients following MI, however, the duration
of DAPT has been debated since the beginning of DAPT [7].
The DAPT trial found reduced ischemic event and increased
bleeding, thus suggesting the extended duration could be used
in patients at high ischemic patients with low bleeding risk
[12]. Subsequently, subgroup studies have been conducted to
define adequate patients for use of extended DAPT therapy.
However, to the best of our knowledge, very few trials have
been conducted in patients with PAD, which were also limited by small sample size. By using meta-analysis, we intended
to combine the limited results together to advance our understanding the role of extended DAPT in patients with PAD undergoing PCI.
This meta-analysis did not detect a significant reduction in
MACCE, cardiac death and all-cause death in extended DAPT
group in patients with PAD after PCI. It seems that the elevated
all-cause death rate in the extended DAPT group is not linked
to the increased bleeding rate [13]. A post-hoc analysis of the
DAPT trial identified a significant difference of cancer related
deaths in both groups (0.6% vs. 0.3%, P = 0.02) [13]. After
adjusting the cancer incidence, a sensitive analysis revealed
a non-significant death rate in both groups, suggesting that
the non-significant reduction of MACCE and all-cause death
may be explained by the imbalanced baseline characteristics
in both groups [13]. In addition, the duration of non-extended
DAPT in the PRODIGY trial was only 6 month [14]. For 50%
of the patients in the PRODIGY trial who received bare mental
stent and first-generation DES, it is recommended to receive
DAPT at least 12-month. The new-generation stents have been
tested in the non-ACS patients showing non-inferior effectiveness in 6-month vs. 12-month [15]. Nevertheless, the duration

Table 2. Effect of PAD on Clinical Outcomes in the DAPT Trial and PRODIGY Trial
DAPT trial

PRODIGY trial

% Patients with % Patients without
PAD (n = 649)
PAD (n = 10,999)

P value

% Patients with
PAD (n = 246)

% Patients without
P value
PAD (n = 1,724)

MACCE

11.65 (73)

4.62 (494)

< 0.001

21.9 (54)

8.4 (144)

< 0.001

MI

5.88 (36)

2.90 (308)

< 0.001

7.5 (18)

3.6 (62)

0.006

Definite/probable ST

1.47 (9)

0.83 (88)

0.094

3.0 (7)

1.2 (21)

0.04

1.74 (185)

< 0.001

2.6 (6)

2.7 (45)

0.95

GUSTO moderate/severe bleeding 4.86 (30)

ST: stent thrombosis; MACCE: major adverse cardiovascular and cerebrovascular event; MI: myocardial infarction.

Articles © The authors | Journal compilation © Cardiol Res and Elmer Press Inc™ | www.cardiologyres.org

141

Treatment Duration of DAPT in PAD Patients After PCI
of DAPT in ACS patients with new-generation stent has not
been fully examined. Therefore, the increased incidence of
MACCE and cardiac-death in the non-extended DAPT group
could be attributed to the increased stent thrombosis events because of insufficient protection from the short duration DAPT
(6-month).
The GUSTO moderate and severe bleeding risk was not
significantly increased in the extended DAPT group in our
meta-analysis. This result is consistent with a recent metaanalysis of 21,534 participants from three trials of post-MI patients received DAPT beyond 12-month [16]. The odds ratio of
major bleeding and fatal bleeding were 1.53 (0.92, 2.52) and
1.12 (0.66, 1.90) with both P values higher than 0.05. (P = 0.10
and P = 0.69). In the PEGASUS-TIMI 54 trial subanalysis,
neither TIMI major nor minor bleeding was associated with
extended DAPT in patients with PAD [6]. In the CHARISMA
trial subanalysis, there was no significant difference in the rate
of severe, fatal, or moderate bleeding, though minor bleeding
was reported to increase almost 2-fold in the extended DAPT
group in the CHARISMA trial [8].
There were high levels of heterogeneity in the analyses of
MACCE, cardiac death and all-cause death, which could be
explained by the differences between the two trials in treatment lengths and baseline characteristics of study participants,
though little heterogeneity was observed in stent thrombosis,
MI, and GUSTO moderate/severe bleeding. Participants in
the PRODIGY trial were more likely to have older age and
previous MI. It was reported that more than 50% participants
had acute MI at presentation in the PRODIGY trial, and less
than 25% patients had stable CAD compared to 45% patients
with stable CAD in the DAPT trial. Hence, patients in the
PRODIGY trial presented more acute conditions, and thereby
might benefit more from the extended DAPT. Also as aforementioned, there was an imbalance of cancer in the baseline
characteristics between groups in the DAPT trial, potentially increased the all-cause death rate in the treatment group.
Furthermore, the duration of non-extended DAPT group was
6-month in PRODIGY trial vs. 12-month in the DAPT trial. Patients in the non-extended DAPT group (6-month) of
PRODIGY trial was associated with significant increase in
MACCE and a non-significant change of definite or probable
stent thrombosis, indicating short duration DAPT (6-month)
may not be able to provide enough protection in ACS patients
with a comorbidity of PAD receiving new-generation DES,
causing overestimation of the benefits of extended DAPT in
MACCE in our results.
There are certain limitations in our meta-analysis. Although we have conducted a comprehensive search by two
persons independently, only two randomized clinical trials
were eligible and included in our study. Theoretically, two trials are the minimal requirement to conduct a meta-analysis,
and more studies provide a more precise estimation of the
true effect than each trial alone. To achieve valid statistical
inferences, the random-effects method was used to combine
treatment effects when the presence of between-trial heterogeneity is suspected. The combination of only a few studies
is not uncommon, especially in cases of rare diseases [17]. In
an analysis of 22,453 meta-analyses from the Cochrane Database of Systematic Reviews, more than one third of the meta142
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analyses included the minimum requirement of two studies
only, and close to 75% meta-analyses contained five or fewer
studies [18]. Nevertheless, the meta-analysis of only two studies in the presence of heterogeneity may be considered an unsolved problem and beyond the scope of this study [19]. We
acknowledge that the low number of studies makes it difficult
to estimate the between-studies variance in random-effects
analysis, and some of our results should be interpreted with
caution. Moreover, procedural factors of the initial PCI play
a major role in determining the risk of ischemic events. For
example, it must be noted that substantial patients received
new-generation DES in both trials, however, the percentage
of participants with new-generation DES was not reported in
their subanalysis. New-generation of DES has been reported
with 50% less risk of stent thrombosis compared with the firstgeneration stent. Indeed, the recent guidelines suggested that
6-month DAPT is reasonable after new-generation DES implantation in patients with stable CAD. Unfortunately, because
of the nature of our data, we had no access to patients’ specific
data thus were not able to identify if the percentage of newgeneration DES implantation will affect our results.
Conclusions
Patients with PAD undergoing PCI are at elevated risk of cardiovascular morbidity and mortality due to increased ischemic
and bleeding events. Among patients with PAD, extended
DAPT after PCI resulted in a non-significant difference in
MACCE, cardiac death, all-cause death and bleeding events
and a significant reduction in stent thrombosis and MI compared to placebo. The review was limited by the small number
of published trials and high level of heterogeneity in MACCE,
cardiac death and all-cause death. Our results showed that the
routine use of extended DAPT in patients with PAD undergoing PCI provided a neutral effect on cardiac outcomes, and
further studies with adequate power are needed to substantiate
the role of extended DAPT in this cohort, especially with newgeneration DES.
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